Company Profile

Shire specializes in developing, producing, and marketing pharmaceutical products for the treatment of nervous system dysfunctions (hyperactivity, epilepsy, Alzheimer's disease, etc.), cancer, gastro-intestinal illnesses, and infectious diseases. Net sales break down by source of income as follows: - sales of products (95.3%); - other (4.7%): primarily franchise royalties. Net sales break down geographically as follows: the United States (63.6%), Ireland (0.4%) and other (36%).

Employees

Sector

Pharmaceuticals

More about the company

21/18/21	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/18/21	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE
20/18/20	British shares falter as Fed, oil play Scrooge	RE
19/18/19	FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	RE
18/18/18	FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	RE
17/18/17	FTSE : down sharply as ASOS profit alert sparks wider retail selloff	RE
07/18/07	FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	RE
05/18/05	FTSE : falls as growth angst spreads	RE
05/18/05	Growth and trade nerves grind European shares down to two-week low	RE
05/18/05	Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	RE
05/18/05	Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	RE
21/18/21	Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	RE
21/18/21	Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	RE

13/20/13	Takeda Pharmaceutical : Drugmaker Takeda expects 35% rise in net profit on lower buyout costs	AQ
04/20/04	Takeda Pharmaceutical : lifts FY 2019 earnings projections after Shire buyout	AQ
07/19/07	Shire : Form 8.3 - Takeda Pharmaceutical	PU
07/19/07	Shire : Form 8.3 -	PU
07/19/07	Shire : Form 8.5 (EPT/RI) - Replacement of Shire	PU

08/19/08	EN DIRECT DES MARCHES : Nissan, Dassault Aviation, STMicroelectronics, Sika, Samsung, Tessi...
07/19/07	Les affaires reprennent dans la pharmacie
21/18/21	Walt Disney : Le marché du M&A se prépare à une année 2019 moins faste
18/18/18	Shire : plombé par le déclassement de Takeda
05/18/05	Altran Technologies : Les craintes sur les taux et le commerce font plier les actions en Europe

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SHIRE	+2.42%	-.--%	-	-	0
ELI LILLY AND COMPANY	-2.33%	-2.09%	+49.88%	+170.51%	1,06000Cr
JOHNSON & JOHNSON	-0.82%	-2.30%	+63.79%	+62.00%	62TCr
ABBVIE INC.	-0.73%	-4.98%	+28.91%	+82.99%	44TCr
ROCHE HOLDING AG	+0.33%	-1.17%	+31.07%	+27.09%	33TCr
NOVARTIS AG	-0.02%	-2.85%	+29.15%	+45.24%	28TCr
ASTRAZENECA PLC	-3.89%	-11.22%	+22.81%	+27.30%	27TCr
NOVO NORDISK A/S	+0.66%	-1.42%	-26.59%	-37.71%	22TCr
AMGEN INC.	-0.06%	-2.88%	+23.07%	+62.33%	20TCr
GILEAD SCIENCES, INC.	-3.72%	-1.10%	+18.41%	+70.56%	16TCr
Average	-0.82%	-3.25%	+26.72%	+56.70%	39.71TCr
Weighted average by Cap.	-1.31%	-2.96%	+36.75%	+83.91%

Shire Share Price

Stocks

JE00B2QKY057

Pharmaceuticals

Latest news : Shire

Analysts' recommendations: Shire

Press Releases: Shire

News in other languages: Shire

Quotes and Performance

Other Pharmaceuticals

Company Profile